Myostatin functions by binding to the activin type II receptors (ActRIIB) on the surface of muscle cells. This binding initiates a signaling cascade that involves the Smad proteins, ultimately leading to the inhibition of muscle growth. By blocking the activity of myostatin, muscle growth can be enhanced, which is why myostatin inhibitors are being researched for their potential to treat muscle-wasting diseases.
